(Press-News.org) French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
At the IMPAKT Breast Cancer Conference in Brussels, Dr François-Clement Bidard and colleagues from Institut Curie in Paris say their new findings set the scene for interventional trials designed to see if improved outcomes can be achieved by modifying treatment based on circulating tumor cell counts.
"We needed to do this study to confirm data provided by earlier small studies," Dr Bidard said. "Now we are certain that circulating tumor cells (CTC) are prognostic at baseline, and that CTC changes under treatment may be an early indicator of chemotherapy efficiency."
"In metastatic breast cancer, it is time now for interventional randomized trials which will try to demonstrate that CTC-based strategies of treatment lead to a better clinical outcome, or at least to a benefit in the cost/efficacy ratio of treatment," Dr Bidard said.
The French team conducted a prospective study in 267 patients who were receiving first-line chemotherapy for metastatic breast cancer. For each patient they performed a count of circulating tumor cells, plus an analysis of other blood markers, in 7.5ml of blood. They took their measurements at the beginning of treatment and at several later time points.
Of 260 patients who were evaluable for CTC levels at baseline, 170 (65%) had at least one circulating tumor cell per 7.5 ml blood sample, and 115 (44%) had five or more, the researchers found.
At the end of the study, a multivariate analysis of their results showed that several factors, including CTC counts, were correlated with disease progression and overall survival.
"This is the first study that has been prospectively designed and statistically powered for reporting CTC-associated outcome as primary endpoint in a homogeneous population of metastatic breast cancer patients treated first line," Dr Bidard said.
The study results also add evidence to an ongoing discussion about how many CTCs per blood sample should be used to define patients at 'high risk' for a poor outcome.
"Generally, the more CTC you have, the worse it is," Dr Bidard said. "However, to define a 'high risk group', a threshold is needed. We report that the relative risk of the high-risk group vs low-risk group does not significantly change whether you define it as having a threshold of 1 CTC or 5 CTC. In both cases, their relative risks of shorter progression-free survival compared to the low-risk group are statistically the same."
"Our data suggest that using the lower threshold of 1 CTC is feasible and is not affected by any major loss of specificity of CTC detection. This supports the use of this low threshold in other studies conducted in non-metastatic breast cancer patients."
Commenting the study, which he was not involved in, Prof Fortunato Ciardiello, from Seconda Università di Napoli, Naples, Italy, noted that circulating tumor cells have been suggested in recent times as a useful prognostic marker for several cancers, including breast cancer.
"This study is very relevant, since it gives a prospective evaluation of the role of CTC in a large series of metastatic breast cancer patients receiving first-line treatment. It represents a significant contribution confirming the prognostic role of CTC and gives important insights to establish a clinically useful threshold level for defining patients with high or low circulating tumor cells."
INFORMATION: END
The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, Belgian researchers have reported.
Epigenetics is a term used to describe modifications to the DNA molecule that affect way its code is translated into proteins. These changes include methylation, a form of chemical modification.
Although researchers knew epigenetics was important in cancer, information about its exact contribution to breast carcinogenesis was scant, Dr Sarah Dedeurwaerder, from Université ...
German researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy.
Triple-negative breast cancers --which do not express the genes for estrogen receptor, or progesterone receptor and do not have Her2/neu overexpression or amplification-- are more aggressive than other forms of the disease and cannot be treated with endocrine or Her2 targeted therapies.
At the IMPAKT Breast Cancer Conference in Brussels, PhD student Carolin Huelsewig and Dr Cornelia Liedtke from Uniklinikum Muenster ...
Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows.
In recent years, several genomic tests have been developed to provide prognostic information for breast cancer. Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, Ireland, and colleagues in the USA examined the agreement in prediction results between two multi-gene assays ...
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies.
At the IMPAKT Breast Cancer Conference in Brussels, Dr Gargi Patel from the Richard Dimbleby Department, King's College London, described cutting-edge research in which she and colleagues captured detailed information about protein interactions on cancer cells, and correlated that with established genetic markers for cancer ...
The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.
The results of a randomized trial in 45 patients with primary invasive breast cancer showed that the drug --which is currently used to treat arthritis and other painful conditions-- clearly induced an anti-tumor response at the molecular level.
"This is exciting because it means that a medication already used to treat other diseases may be efficient in the adjuvant treatment of breast cancer ...
Domenico Di Ceglie, Director of Training and Research at the Gender Identity Development Service at the Tavistock and Portman NHS Foundation Trust in London, commented: "These are important findings in the field of gender incongruence, which need to be replicated. The awareness of the presence of autistic features may help these young people to explore the reasons behind their perceptions, and help them make more informed decisions about treatment."
Emma Martin, who runs a Gender Identity Support and research group in Little Downham, UK, welcomed the new findings, and ...
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
The biosensor has been developed by researchers at the Virginia Institute of Marine Science (VIMS) and was tested in the Elizabeth River and Yorktown Creek which both drain into Virginia's Chesapeake Bay.
"Our biosensor combines the power of the immune system ...
Spine Surgeon LA, the leading spine surgery specialists in the state of California has recently launched their website at the URL www.spinesurgeonla.com
Spine Surgeon LA is a medical hub wherein they treat and address several different types of spine problems. These spine problems include: Bulging Disc, Herniated Disc, Spine Scoliosis, Pinched Nerve, Spine Stenosis, Bone Spurs, and Spine Tumors among others. In their new website, spinesurgeonla.com, you may click on these common spine problems and then get a chance to read some information about them so that you may ...
Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.
University of Manchester researchers, working with colleagues in Newark, USA, have developed a new test that can not only better diagnose Aspergillus infection, but can also spot signs of antifungal resistance to azoles – the class of drugs used to treat patients with aspergillosis.
Using the new test, which uses direct molecular detection rather than culturing the fungus in a Petri dish, the ...
The recent nuclear accident in Fukushima Daiichi in Japan has brought the nuclear debate to the forefront of controversy. While Japan is trying to avert further disaster, many nations are reconsidering the future of nuclear power in their regions. A study by Behnam Taebi from the Delft University of Technology, published online in the Springer journal Philosophy & Technology, reflects on the various possible nuclear power production methods from an ethical perspective: If we intend to continue with nuclear power production, which technology is most morally desirable?
On ...
